Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (2)

Trial Status

Unknown3
Terminated1
Active Not Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT04003857Phase 2Active Not Recruiting

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

NCT04440670Phase 3UnknownPrimary

Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates

NCT05972096Not ApplicableUnknown

DBT Skills Expanded With Contextual Intervention for Long Lasting Symptoms in Borderline Personality Disorder

NCT02149823Phase 1Terminated

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT05071638Phase 3UnknownPrimary

Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates

Showing all 5 trials

Research Network

Activity Timeline